questionsmedicales.fr
Thérapeutique
Thérapie respiratoire
Oxygénothérapie
Oxygénation hyperbare
Oxygénation hyperbare : Questions médicales fréquentes
Termes MeSH sélectionnés :
Programmed Cell Death 1 Receptor
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Oxygénation hyperbare : Questions médicales les plus fréquentes",
"headline": "Oxygénation hyperbare : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Oxygénation hyperbare : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-26",
"dateModified": "2025-04-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Oxygénation hyperbare"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Oxygénothérapie",
"url": "https://questionsmedicales.fr/mesh/D010102",
"about": {
"@type": "MedicalCondition",
"name": "Oxygénothérapie",
"code": {
"@type": "MedicalCode",
"code": "D010102",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.880.690"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Oxygénation hyperbare",
"alternateName": "Hyperbaric Oxygenation",
"code": {
"@type": "MedicalCode",
"code": "D006931",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Richard E Moon",
"url": "https://questionsmedicales.fr/author/Richard%20E%20Moon",
"affiliation": {
"@type": "Organization",
"name": "Departments of Anesthesiology and Medicine, Center for Hyperbaric Medicine and Environmental Physiology, Duke University, North Carolina U.S."
}
},
{
"@type": "Person",
"name": "John P Kirby",
"url": "https://questionsmedicales.fr/author/John%20P%20Kirby",
"affiliation": {
"@type": "Organization",
"name": "John P. Kirby MD, FACS, is the Director of Wound Healing Programs, Associate Professor of Surgery, Section of Acute and Critical Care Surgery, at Washington University School of Medicine, Barnes-Jewish Hospital, in St. Louis, Missouri."
}
},
{
"@type": "Person",
"name": "Stephen R Thom",
"url": "https://questionsmedicales.fr/author/Stephen%20R%20Thom",
"affiliation": {
"@type": "Organization",
"name": "Emergency Medicine, University of Maryland, Baltimore, MD, USA."
}
},
{
"@type": "Person",
"name": "Michael H Bennett",
"url": "https://questionsmedicales.fr/author/Michael%20H%20Bennett",
"affiliation": {
"@type": "Organization",
"name": "Department of Diving and Hyperbaric Medicine, Prince of Wales Hospital and University of New South Wales, Sydney, New South Wales, Australia."
}
},
{
"@type": "Person",
"name": "Simon J Mitchell",
"url": "https://questionsmedicales.fr/author/Simon%20J%20Mitchell",
"affiliation": {
"@type": "Organization",
"name": "Department of Anaesthesiology, University of Auckland Faculty of Medicine, Auckland, New Zealand."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.",
"datePublished": "2023-01-24",
"url": "https://questionsmedicales.fr/article/36645031",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/exd.14750"
}
},
{
"@type": "ScholarlyArticle",
"name": "MicroRNAs Targeting Programmed Cell Death Protein 1 (PD-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis.",
"datePublished": "2022-12-24",
"url": "https://questionsmedicales.fr/article/36640056",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18502/ijaai.v21i6.11524"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy.",
"datePublished": "2023-04-21",
"url": "https://questionsmedicales.fr/article/37153623",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1138145"
}
},
{
"@type": "ScholarlyArticle",
"name": "A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.",
"datePublished": "2022-09-06",
"url": "https://questionsmedicales.fr/article/35758515",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2340/actadv.v102.1062"
}
},
{
"@type": "ScholarlyArticle",
"name": "Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.",
"datePublished": "2022-11-25",
"url": "https://questionsmedicales.fr/article/36442821",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.actbio.2022.11.043"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Thérapeutique",
"item": "https://questionsmedicales.fr/mesh/D013812"
},
{
"@type": "ListItem",
"position": 3,
"name": "Thérapie respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012138"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxygénothérapie",
"item": "https://questionsmedicales.fr/mesh/D010102"
},
{
"@type": "ListItem",
"position": 5,
"name": "Oxygénation hyperbare",
"item": "https://questionsmedicales.fr/mesh/D006931"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Oxygénation hyperbare - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Oxygénation hyperbare",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Oxygénation hyperbare",
"description": "Comment diagnostiquer une décompression ?\nQuels tests pour l'oxygénation hyperbare ?\nQuels symptômes indiquent un traitement ?\nComment évaluer l'efficacité du traitement ?\nQuels critères pour l'admission en chambre hyperbare ?",
"url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Oxygénation hyperbare",
"description": "Quels sont les symptômes de l'oxygénation hyperbare ?\nComment se manifeste l'intoxication à l'oxygène ?\nQuels signes d'une embolie gazeuse ?\nQuels symptômes après une séance d'oxygénation ?\nComment reconnaître une réaction allergique ?",
"url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Oxygénation hyperbare",
"description": "Comment prévenir la maladie de décompression ?\nQuelles précautions avant une séance ?\nComment éviter l'intoxication à l'oxygène ?\nQuelles sont les recommandations post-traitement ?\nComment se préparer psychologiquement ?",
"url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Oxygénation hyperbare",
"description": "Quelles conditions traitent l'oxygénation hyperbare ?\nComment se déroule une séance d'oxygénation ?\nQuelle est la durée d'une séance ?\nY a-t-il des effets secondaires ?\nQui peut administrer ce traitement ?",
"url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Oxygénation hyperbare",
"description": "Quelles complications peuvent survenir ?\nComment gérer une embolie gazeuse ?\nQuels risques liés à l'oxygénation hyperbare ?\nComment prévenir les infections en chambre ?\nQuels signes d'une complication grave ?",
"url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Oxygénation hyperbare",
"description": "Quels sont les facteurs de risque de décompression ?\nQui est à risque d'intoxication à l'oxygène ?\nQuels antécédents augmentent les risques ?\nComment l'âge influence-t-il les risques ?\nQuels médicaments augmentent les risques ?",
"url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une décompression ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic de décompression se fait par l'évaluation des symptômes et des antécédents d'immersion."
}
},
{
"@type": "Question",
"name": "Quels tests pour l'oxygénation hyperbare ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie et des évaluations cliniques sont utilisés pour déterminer l'indication."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un traitement ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des douleurs articulaires, des troubles neurologiques ou des brûlures peuvent indiquer un traitement."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du traitement ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par l'amélioration des symptômes et des tests de suivi après traitement."
}
},
{
"@type": "Question",
"name": "Quels critères pour l'admission en chambre hyperbare ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent des conditions médicales spécifiques et l'absence de contre-indications."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'oxygénation hyperbare ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des douleurs, des vertiges, et des troubles de la vision."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'intoxication à l'oxygène ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'intoxication à l'oxygène se manifeste par des convulsions, des nausées et des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Quels signes d'une embolie gazeuse ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des douleurs thoraciques, des difficultés respiratoires et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes après une séance d'oxygénation ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Après une séance, des sensations de fatigue ou de légers maux de tête peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une réaction allergique peut se manifester par des éruptions cutanées, des démangeaisons ou un gonflement."
}
},
{
"@type": "Question",
"name": "Comment prévenir la maladie de décompression ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut une ascension lente après la plongée et des pauses de sécurité."
}
},
{
"@type": "Question",
"name": "Quelles précautions avant une séance ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez de fumer, de consommer de l'alcool et informez le médecin de vos antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Comment éviter l'intoxication à l'oxygène ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pour éviter l'intoxication, respectez les protocoles de traitement et les durées recommandées."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations post-traitement ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Après traitement, reposez-vous et évitez les activités physiques intenses pendant 24 heures."
}
},
{
"@type": "Question",
"name": "Comment se préparer psychologiquement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Préparez-vous en vous informant sur le traitement et en discutant avec des professionnels."
}
},
{
"@type": "Question",
"name": "Quelles conditions traitent l'oxygénation hyperbare ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle traite des conditions comme la maladie de décompression, les infections et les brûlures."
}
},
{
"@type": "Question",
"name": "Comment se déroule une séance d'oxygénation ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une séance se déroule dans une chambre pressurisée où le patient respire de l'oxygène pur."
}
},
{
"@type": "Question",
"name": "Quelle est la durée d'une séance ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une séance dure généralement entre 60 et 120 minutes, selon la condition traitée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des douleurs aux oreilles, des nausées ou des troubles visuels."
}
},
{
"@type": "Question",
"name": "Qui peut administrer ce traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement doit être administré par des professionnels de santé formés en médecine hyperbare."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des lésions pulmonaires, des convulsions et des infections."
}
},
{
"@type": "Question",
"name": "Comment gérer une embolie gazeuse ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une embolie gazeuse nécessite une intervention rapide, souvent avec une oxygénation hyperbare."
}
},
{
"@type": "Question",
"name": "Quels risques liés à l'oxygénation hyperbare ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des barotraumatismes, des troubles de la vision et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections en chambre ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pour prévenir les infections, maintenez une bonne hygiène et suivez les protocoles de désinfection."
}
},
{
"@type": "Question",
"name": "Quels signes d'une complication grave ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques intenses ou des troubles neurologiques nécessitent une attention immédiate."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de décompression ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent la profondeur de plongée, la durée et l'absence de pauses de sécurité."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'intoxication à l'oxygène ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les plongeurs et les patients recevant une oxygénation hyperbare à haute pression sont à risque."
}
},
{
"@type": "Question",
"name": "Quels antécédents augmentent les risques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de troubles respiratoires ou neurologiques peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il les risques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent avoir un risque accru de complications en raison de la fragilité des tissus."
}
},
{
"@type": "Question",
"name": "Quels médicaments augmentent les risques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments, comme les diurétiques, peuvent augmenter le risque de déshydratation et de complications."
}
}
]
}
]
}
Melanoma is a highly aggressive tumor derived from melanocytes. In recent years, the incidence and mortality of melanoma have gradually increased, seriously threatening human health. Classic treatment...
Natural killer (NK) cells play a role in the pathogenesis of rheumatoid arthritis (RA). Upregulated levels of programmed cell death protein 1 (PD-1) is a sign of exhausted NK cells that could be regul...
Leprosy is a chronic bacterial disease caused by...
Erythroderma is challenging to diagnose. The aim of this single-centre retrospective study was to identify factors that can be used to improve the diagnosis of erythroderma. Among 91 patients with ery...
Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand programmed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, includi...
The immune system uses various immune checkpoint axes to adjust responses, support homeostasis, and deter self-reactivity and autoimmunity. Nevertheless, non-small-cell lung carcinoma (NSCLC) can use ...
Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC) by the European...
Post hoc analysis of the Chinese JUPITER-06 study focusing on efficacy stratified by PD-L1 tumor proportion score (TPS; using JS311 antibody) was conducted. Electronic databases were searched to ident...
The post hoc analysis of JUPITER-06 showed more prominent clinical benefit with PD-1 antibody plus chemotherapy than with chemotherapy alone in both the high and low PD-L1-expressing subgroups. Five r...
This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of pred...
Major depression (MD) may be associated with inflammation and immunity. PD-1 (programmed death-1), PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2) are among the inhibitory immu...
During a period of 2 years, patients with MD and healthy controls were recruited from a medical centre in this study. The diagnosis of MD was established according to the DSM-5 criteria. The severity ...
A total of 54 patients with MD and 38 healthy controls were recruited. According to the analyses, there is a significantly higher PD-L2 level in MD than in healthy controls and lower PD-1 level after ...
It was found that PD-1 pathway might play an important role in MD. We need a large sample to prove these results in the future....
Tumor-infiltrating lymphocytes are detectable in up to 75% of triple-negative breast cancer. The composition of these infiltrates may influence prognosis and is not known regarding regulatory or effec...
This was a retrospective observational study. Clinical and pathological data from 38 triple-negative breast cancer patients treated with neoadjuvant chemotherapy at the University Hospital (HUCFF/UFRJ...
Statistically significant changes in stromal tumor-infiltrating lymphocyte categories were observed before and post-neoadjuvant chemotherapy, with 32% of intermediate cases becoming high. The correlat...
In this study, we observed that chemotherapy significantly increases stromal tumor-infiltrating lymphocytes, CD8 T cells, as well as CD8/FoxP3 ratio. Most importantly, programmed cell death protein 1 ...
Melanoma is widely treated with programmed cell death-1 (PD-1) inhibitors. As part of their anti-tumor immunity effect, they increase the susceptibility to cutaneous immune-related adverse events (cIR...